Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single Ascending Dose Pharmacokinetic and Safety Study of LY03004 Following Escalating Single Intramuscular Injection in Stable Patients With Schizophrenia or Schizoaffective Disorder

NCT02055287 is registered in ClinicalTrials.gov with Luye Pharma Group Ltd. as lead sponsor.

NCT NCT02055287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02055287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single Ascending Dose Pharmacokinetic and Safety Study of LY03004 Following Escalating Single Intramuscular Injection in Stable Patients With Schizophrenia or Schizoaffective Disorder
Lead sponsor
Luye Pharma Group Ltd.
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2013
Completion date
June 30, 2014
Enrollment
36 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia